DEBIO 9902

Drug Profile

DEBIO 9902

Alternative Names: DEBIO 9902 SR; DEBIO-9902 SR implants; N-(5-chloro-2-hydroxy-3-methoxy-benzylidene)-huperzine A; Oral ZT 1; ZT 1 Long Acting; ZT 1 sustained-release SC implant; ZT-1; ZT-1 LA

Latest Information Update: 25 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chinese Academy of Sciences; Jiangsu Yangtze Pharma
  • Developer Debiopharm
  • Class Alkaloids; Antidementias; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 23 Oct 2008 Debiopharm Group completes phase II (BRAINz) trial in Alzheimer's disease
  • 21 Oct 2008 Phase-I clinical trials in Alzheimer's disease of new tablet formulation in healthly elderly volunteers in USA (PO)
  • 06 Mar 2008 The phase II (BRAINz) trial is ongoing for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top